News | Heart Valve Technology | November 10, 2016

First Patient Treated in U.S. Trial of NeoChord DS1000 System

RECHORD Trial will assess safety and effectiveness of off-pump, minimally invasive repair device for degenerative mitral regurgitation

NeoChord, RECHORD Trial, first patient, DS1000 System, degenerative mitral regurgitation, DMR

November 10, 2016 — NeoChord Inc. announced the first use of its DS1000 System in the United States as it enrolled the first patient in the RECHORD Trial.

The RECHORD Trial is a prospective, multicenter, randomized U.S. Food and Drug Administration (FDA) pivotal study intended to establish the safety and effectiveness of the DS1000 System as an alternative to standard surgical mitral valve repair. The study was approved to enroll up to 585 subjects at up to 20 U.S. centers. This study is the first trial of its kind to treat degenerative mitral regurgitation (DMR) patients that have ruptured or elongated chordae tendinae in a trans-apical, beating heart procedure.

David H. Adams, M.D., cardiac surgeon-in-chief, Mount Sinai Health System, and his team successfully treated the first patient in the RECHORD Trial at The Mount Sinai Hospital in New York, N.Y. Adams, national co-principal investigator of the trial, noted, “The success that we observed with our first patient in the trial is very promising and is indicative of the strong clinical results observed in Europe in appropriately selected patients with degenerative mitral valve regurgitation.”

“NeoChord’s technology has the potential to empower surgeons to intervene earlier in the disease process than previously possible and before significant ventricular changes occur,” said Co-Principal Investigator Michael A. Borger, M.D., Ph.D., professor and director, Cardiovascular Institute, New York Presbyterian Hospital/Columbia University Medical Center in New York, NY. “Clinical evidence that demonstrates the benefit of earlier intervention would truly transform the surgical treatment paradigm for patients suffering from DMR.”

In standard mitral valve repair procedures, patients are placed on cardiopulmonary bypass — the heart is arrested while the mitral valve is exposed and repaired. NeoChord’s DS 1000 System technology allows for a truly minimally invasive procedure via a transapical puncture on a beating heart without the need for cardio-pulmonary bypass or aortic cross-clamping. As a result, the invasiveness of the repair procedure is significantly reduced. With the NeoChord procedure, the surgeon uses real-time echocardiographic feedback in the operating room (OR) to precisely adjust the length of the newly placed chords and to reduce and/or eliminate mitral valve regurgitation, while the heart is beating and functioning.

The NeoChord DS1000 System is CE marked and approved for sale in Europe. It is an investigational device in the United States, limited by federal law to investigational use.

For more information: www.neochord.com


Related Content

News | Heart Valve Technology

July 10, 2025 — On July 2, 2025, Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Determination ...

Home July 11, 2025
Home
News | Heart Valve Technology

June 27, 2025 – Foldax Inc., a leader in the development of innovative polymer heart valves, has announced compelling ...

Home June 27, 2025
Home
News | Heart Valve Technology

June 04, 2025 — HeartSciences Inc. has announced that the U.S. Food and Drug Administration has granted Breakthrough ...

Home June 12, 2025
Home
News | Heart Valve Technology

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne ...

Home May 28, 2025
Home
News | Heart Valve Technology

May 2, 2025 – New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the ...

Home May 02, 2025
Home
News | Heart Valve Technology

April 28, 2025 — The Society of Thoracic Surgeons (STS) has launched its latest surgical risk calculator designed for ...

Home April 29, 2025
Home
News | Heart Valve Technology

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data ...

Home March 31, 2025
Home
News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
News | Heart Valve Technology

Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is ...

Home February 18, 2025
Home
Subscribe Now